P=N/A, N=3, Not yet recruiting, Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine; Shanghai Children's Medical Center, Shanghai Jiao Tong Universit

P1b/2, N=80, Terminated, Veru Inc. | N=58 --> 80 | Completed --> Terminated; Administrative decision

P3, N=105, Terminated, Veru Inc. | N=245 --> 105 | Trial completion date: Sep 2024 --> May 2023 | Active, not recruiting --> Terminated | Trial primary completion date: May 2024 --> May 2023; Administrative reasons

P1b/2, N=58, Completed, Veru Inc. | Active, not recruiting --> Completed | N=41 --> 58

P2, N=0, Withdrawn, Veru Inc. | N=200 --> 0 | Not yet recruiting --> Withdrawn

This study developed a robust IGS model for survival prediction of HCC patients, providing new insights into integrating tailored risk stratification with precise immunotherapy and screening potentially targeted agents.

P3, N=245, Active, not recruiting, Veru Inc. | Recruiting --> Active, not recruiting

Preferred frontline treatment relies on anti-HER2 therapies, such as trastuzumab and pertuzumab, combined with microtubule inhibitors, such as taxanes. While sabizabulin shows promising results for treatment in HER2+ breast cancer, we further optimized the structure of sabizabulin to create a new class of anti-cancer molecules: 40a, CH-2-77, and 60c. Based on in vitro data, 60c showed higher potency in HER2+ breast cancer cell lines and was chosen as the lead compound to further study in a paclitaxel-resistant triple negative breast cancer in vivo study where it was able to effectively inhibit primary tumor growth compared to the vehicle group.

This clinical trial demonstrated that chronic oral daily dosing of sabizabulin has a favorable safety profile with significant preliminary cytotoxic and cytostatic antitumor activity. These data support the ongoing Phase 3 VERACITY trial of sabizabulin in men with mCRPC who have progressed on an androgen receptor targeting agent.

P2, N=200, Not yet recruiting, Veru Inc. | Trial completion date: Feb 2024 --> May 2024 | Trial primary completion date: Dec 2023 --> Mar 2024

P1b/2, N=41, Active, not recruiting, Veru Inc. | Trial completion date: Nov 2022 --> Apr 2023 | Trial primary completion date: Sep 2022 --> Feb 2023

Herein, we report a retrospective analysis of patients with newly diagnosed Ph+ ALL who received olverembatinib plus low-intensive regimen (VP: Vindesine + dexamethasone / prednisone ) at our institution.Olverembatinib was administered at a dose of 40 mg orally QOD continuously...The choice of sequentially consolidation treatment with allogeneic hematopoietic stem-cell transplantation (allo-HSCT), blinatumomab or intensive chemotherapy, was made by the investigators and patients preference. Prophylactic intrathecal chemotherapy with cytarabine and dexamethasone was administered in each cycle...Conclusion s : Olverembatinib was well tolerated and showed high early response in newly diagnosed Ph +ALL. These promising findings warrant further investigation in future trials.